Bayer’s June Crucible: A Glaucoma Drug, a Glyphosate Verdict, and a Debt Mountain
23.06.2026 - 08:41:55 | boerse-global.de
On 17 June 2026, Bayer closed its acquisition of Perfuse Therapeutics, acquiring full rights to PER?001, a Phase II candidate for glaucoma. The $300 million upfront payment — which could rise to $2.45 billion with milestones — signals the company’s determination to reinvent its pharmaceuticals business before patent expiries on Eylea and Xarelto bite harder. But the real focus for investors this month is less about what Bayer is buying and more about what the US Supreme Court will rule.
The justices are deliberating Durnell, a case that tests the legal doctrine of preemption. If federal law on warning labels overrides state?level claims for allegedly inadequate warnings, roughly 65,000 glyphosate lawsuits against Bayer would evaporate. A win would also clear the path for the preliminary settlement agreement in Missouri, where a final approval hearing is set for 9 July 2026.
Bayer’s stock ended the latest session at €38.07, barely above its 50?day moving average of €37.76. That tight range reflects the binary nature of the next few days: a favorable ruling could unlock a re?rating, while an adverse one would renew fears over a balance sheet stretched by €32.5 billion in net debt.
Operationally, the picture is more encouraging. First?quarter currency?adjusted revenue hit €13.4 billion, and underlying operating profit rose to around €4.45 billion. New products such as Nubeqa and Kerendia are already delivering meaningful sales growth. Meanwhile, the European Medicines Agency has validated the marketing application for asundexian, and the FDA is reviewing the same drug under accelerated conditions, with a decision possible in the second half of 2026.
Should investors sell immediately? Or is it worth buying Bayer?
PER?001 is a novel endothelin receptor blocker — no similar drug has yet been approved for eye diseases. But Phase II candidates often stumble in later trials, and the road to commercial launch remains long. The real short?term catalyst remains the Supreme Court.
UBS analyst Matthew Weston puts the odds of a Bayer victory at 70%. If that happens, the Missouri settlement — already provisionally approved — can advance, easing the legal cash drain that cost the company roughly €2 billion in the first quarter alone. That would free up free cash flow to accelerate deleveraging.
Yet risks are piling up elsewhere. The Office of the US Trade Representative is examining German drug?pricing policies, and any retaliation in the form of tariffs or forced rebates would hit Bayer’s lucrative US pharmaceutical margins. Barclays analysts warn that the Missouri settlement faces procedural hurdles, with jurisdictional questions threatening to delay the July hearing.
Bayer at a turning point? This analysis reveals what investors need to know now.
If the Supreme Court rules against Bayer, the debt overhang will dominate again. With interest rates still elevated, refinancing the €32.5 billion net debt becomes costlier, and the dividend hangs in the balance.
The remaining June days are therefore decisive. The verdict will either give Bayer’s pipeline story room to breathe or tighten the legal and financial vice that has squeezed the stock for years. The next set of quarterly results, due in August, will then show whether the new chief financial officer’s restructuring efforts are gaining measurable traction.
Ad
Bayer Stock: New Analysis - 23 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
